DM
MCID: DRM010
MIFTS: 62

Dermatomyositis (DM) malady

Categories: Rare diseases, Neuronal diseases, Nephrological diseases, Bone diseases, Skin diseases, Muscle diseases

Aliases & Classifications for Dermatomyositis

About this section
Sources:
11Disease Ontology, 13DISEASES, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 49NINDS, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Dermatomyositis:

Name: Dermatomyositis 11 48 49 54 50 39 13 68
Amyopathic Dermatomyositis 11 48 68
Adult Dermatomyositis 48 54
Polymyositis with Skin Involvement 11
Dermatopolymyositis, Unspecified 11
 
Dermatomyositis Sine Myositis 48
Adult Type Dermatomyositis 68
Dermatopolymyositis 11
Adm 48
Dm 54

Characteristics:

Orphanet epidemiological data:

54
dermatomyositis:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (Australia),1-9/100000 (Australia),1-9/1000000 (Argentina),1-5/10000 (Argentina),1-9/1000000 (United States),1-9/1000000 (Spain); Age of onset: All ages; Age of death: any age

Classifications:



External Ids:

Disease Ontology11 DOID:10223
ICD1030 M33, M33.9, M33.90
ICD9CM32 710.3
MeSH39 D003882
NCIt45 C26744
Orphanet54 ORPHA221
ICD10 via Orphanet31 M33.1, M33.0
MESH via Orphanet40 D003882
UMLS via Orphanet69 C0011633

Summaries for Dermatomyositis

About this section
NINDS:49 Dermatomyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.  Dermatomyositis’ cardinal symptom is a skin rash that precedes, accompanies, or follows  progressive muscle weakness.  The rash looks patchy, with purple or red discolorations, and characteristically develops on the eyelids and on muscles used to extend or straighten joints, including knuckles, elbows, knees, and toes.  Red rashes may also occur on the face, neck, shoulders, upper chest, back, and other locations, and there may be swelling in the affected areas.  The rash sometimes occurs without obvious muscle involvement.  Adults with dermatomyositis may experience weight loss, a low-grade fever, inflamed lungs, and be sensitive to light such that the rash or muscle disease gets worse.  Children and adults with dermatomyositis may develop calcium deposits, which appear as hard bumps under the skin or in the muscle (called calcinosis).  Calcinosis most often occurs 1-3 years after the disease begins.  These deposits are seen more often in children with dermatomyositis than in adults.  In some cases of dermatomyositis, distal muscles (muscles located away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses.  Dermatomyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus. 

MalaCards based summary: Dermatomyositis, also known as amyopathic dermatomyositis, is related to tuberculosis and rheumatoid arthritis, and has symptoms including exanthema, pruritus and Array. An important gene associated with Dermatomyositis is CHD4 (Chromodomain Helicase DNA Binding Protein 4), and among its related pathways are Signaling events mediated by HDAC Class I and IgA-Producing B Cells in the Intestine. The drugs immunoglobulins, intravenous and potassium aminobenzoate have been mentioned in the context of this disorder. Affiliated tissues include muscle or, skin and lung, and related mouse phenotypes are hematopoietic system and immune system.

NIH Rare Diseases:48 Amyopathic dermatomyositis is a form of dermatomyositis characterized by the presence of typical skin findings without muscle weakness. some of the skin changes that suggest dermatomyositis include a pink rash on the face, neck, forearms and upper chest; gottron's papules and heliotrope eyelids. pruritis and photosensitivity are common, as is scalp inflammation and thinning of the hair. while patients with amyopathic dermatomyositis should not have clinically evident muscle weakness, minor muscle abnormalities may be included. fatigue is reported in at least 50% of patients. some cases have been associated with internal malignancy and/or interstitial lung disease. treatment may include sun avoidance, ample use of sunscreen, topical corticosteroids, antimalarial agents, methotrexate, mycophenolate mofetil, or intravenous (iv) immunoglobulin. last updated: 1/10/2013

Disease Ontology:11 A myositis that results in inflammation located in muscle or located in skin where a skin rash is often seen prior to the onset of muscle weakness. The disease may result from either a viral infection or an autoimmune reaction.

Wikipedia:71 Dermatomyositis (DM) is a rare connective-tissue disease related to polymyositis (PM) that is... more...

Related Diseases for Dermatomyositis

About this section

Diseases in the Dermatomyositis family:

Adult Dermatomyositis

Diseases related to Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 299)
idRelated DiseaseScoreTop Affiliating Genes
1tuberculosis29.7IL17A, PIK3C2A, TNF
2rheumatoid arthritis29.3ICAM1, IL17A, IL1A, TNF, VCAM1
3childhood type dermatomyositis12.3
4adult dermatomyositis12.0
5neonatal dermatomyositis11.9
6c9 deficiency11.6
7polymyositis11.4
8myositis11.4
9myotonic dystrophy 111.3
10maturity-onset diabetes of the young11.2
11diabetes insipidus11.2
12idiopathic inflammatory myopathy11.1
13antisynthetase syndrome11.1
14cryptogenic organizing pneumonia11.1
15epidermolysis bullosa simplex, dowling-meara type11.0
16diaphyseal medullary stenosis with malignant fibrous histiocytoma10.7
17lung disease10.4
18interstitial lung disease10.4
19calcinosis10.3
20infiltrating ureter transitional cell carcinoma10.2CHKB, PIK3C2A, TNF
21right ventricle hypoplasia10.1ICAM1, TNF, VCAM1
22pyelonephritis10.1ICAM1, PIK3C2A, TNF
23erb-duchenne and dejerine-klumpke palsies10.1ICAM1, TNF, VCAM1
24hypotrichosis 410.1ICAM1, IL1A, TNF
25pneumonia10.1
26persistent mullerian duct syndrome10.1ICAM1, TNF, VCAM1
27lupus erythematosus10.1
28dentinogenesis imperfecta10.1ICAM1, PIK3C2A, VCAM1
29asbestosis10.1PIK3C2A, TNF, VCAM1
30periodontosis10.1ICAM1, IL1A, TNF
31balkan nephropathy10.1ICAM1, IL17A, TNF
32pemphigus vulgaris, familial10.1ICAM1, TNF, VCAM1
33lymphedema10.1ICAM1, IL1A, VCAM1
34xanthogranulomatous cholecystitis10.1ICAM1, IL17A, TNF
35orofacial granulomatosis10.1ICAM1, IL1A, VCAM1
36retinal ischemia10.0ICAM1, SFTPD, TNF
37synovium cancer10.0ICAM1, TNF, VCAM1
38optic nerve hypoplasia10.0ICAM1, IL17A, TNF
39skin conditions10.0IL1A, SFTPD, TNF
40aplasia cutis autosomal recessive10.0HARS, KARS, TARS
41pigmentation disease10.0ICAM1, TNF, VCAM1
42neonatal jaundice10.0ICAM1, IL17A, TNF
43inclusion body myositis10.0
44arthritis10.0
45myopathy10.0
46systemic lupus erythematosus10.0
47anaplastic large cell lymphoma10.0ICAM1, IL1A, TNF
48melanoma10.0
49nervous system cancer10.0IFIH1, IL1A, SFTPD, TNF
50microscopic breast papilloma10.0ICAM1, PIK3C2A, TNF

Comorbidity relations with Dermatomyositis via Phenotypic Disease Network (PDN):


Acute CystitisPolymyositis

Graphical network of the top 20 diseases related to Dermatomyositis:



Diseases related to dermatomyositis

Symptoms & Phenotypes for Dermatomyositis

About this section

Human phenotypes related to Dermatomyositis:

 54 64 (show all 52)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the eyelid64 54 Very frequent (99-80%) HP:0000492
2 chondrocalcinosis64 54 Frequent (79-30%) HP:0000934
3 dry skin64 54 Frequent (79-30%) HP:0000958
4 edema54 Very frequent (99-80%)
5 pruritus64 54 Frequent (79-30%) HP:0000989
6 cutaneous photosensitivity64 54 Occasional (29-5%) HP:0000992
7 acrocyanosis64 54 Frequent (79-30%) HP:0001063
8 muscular hypotonia64 54 Frequent (79-30%) HP:0001252
9 arthritis64 54 Frequent (79-30%) HP:0001369
10 abnormality of the nail64 54 Frequent (79-30%) HP:0001597
11 abnormality of the voice54 Occasional (29-5%)
12 dysphonia64 54 Occasional (29-5%) HP:0001618
13 myocardial infarction64 54 Occasional (29-5%) HP:0001658
14 pericarditis64 54 Occasional (29-5%) HP:0001701
15 weight loss64 54 Frequent (79-30%) HP:0001824
16 abnormality of eosinophils64 54 Occasional (29-5%) HP:0001879
17 fever64 54 Occasional (29-5%) HP:0001945
18 pulmonary hypertension54 Occasional (29-5%)
19 respiratory insufficiency64 54 Frequent (79-30%) HP:0002093
20 recurrent respiratory infections64 54 Frequent (79-30%) HP:0002205
21 pulmonary fibrosis64 54 Frequent (79-30%) HP:0002206
22 diffuse reticular or finely nodular infiltrations64 54 Frequent (79-30%) HP:0002207
23 vasculitis64 54 Occasional (29-5%) HP:0002633
24 neoplasm54 Occasional (29-5%)
25 lymphoma64 54 Occasional (29-5%) HP:0002665
26 arthralgia64 54 Frequent (79-30%) HP:0002829
27 autoimmunity64 54 Very frequent (99-80%) HP:0002960
28 breast carcinoma64 54 Occasional (29-5%) HP:0003002
29 myalgia64 54 Very frequent (99-80%) HP:0003326
30 emg abnormality64 54 Very frequent (99-80%) HP:0003457
31 proximal muscle weakness64 54 Very frequent (99-80%) HP:0003701
32 interstitial pulmonary disease54 Frequent (79-30%)
33 aplasia/hypoplasia of the skin64 54 Occasional (29-5%) HP:0008065
34 feeding difficulties in infancy64 54 Occasional (29-5%) HP:0008872
35 inflammatory myopathy64 54 Very frequent (99-80%) HP:0009071
36 erythema64 54 Very frequent (99-80%) HP:0010783
37 abnormal hair quantity64 54 Frequent (79-30%) HP:0011362
38 arrhythmia54 Occasional (29-5%)
39 sinus tachycardia64 54 Occasional (29-5%) HP:0011703
40 fatigue64 54 Frequent (79-30%) HP:0012378
41 myocarditis64 54 Occasional (29-5%) HP:0012819
42 lung adenocarcinoma64 54 Occasional (29-5%) HP:0030078
43 periorbital edema64 54 Very frequent (99-80%) HP:0100539
44 teleangiectasia of the skin54 Occasional (29-5%)
45 cellulitis64 54 Occasional (29-5%) HP:0100658
46 gastrointestinal stroma tumor64 54 Occasional (29-5%) HP:0100723
47 gangrene64 54 Occasional (29-5%) HP:0100758
48 papule64 54 Frequent (79-30%) HP:0200034
49 skin ulcer64 54 Frequent (79-30%) HP:0200042
50 pulmonary arterial hypertension64 HP:0002092
51 interstitial pulmonary abnormality64 HP:0006530
52 telangiectasia of the skin64 HP:0100585

UMLS symptoms related to Dermatomyositis:


exanthema, pruritus

MGI Mouse Phenotypes related to Dermatomyositis according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053977.8CHD4, ICAM1, IFIH1, IL17A, IL1A, PIK3C2A
2MP:00053877.5CHD4, ICAM1, IFIH1, IL17A, IL1A, PIK3C2A
3MP:00107685.5AARS, CHD4, GARS, ICAM1, IFIH1, IL17A

Drugs & Therapeutics for Dermatomyositis

About this section

Drugs for Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 111)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
AbataceptapprovedPhase 4, Phase 3, Phase 2197332348-12-610237
Synonyms:
CTLA4-Ig
 
CTLA4-IgG4m
CTLA4Ig
CTLA4IgG4m
2
PirfenidoneinvestigationalPhase 45553179-13-840632
Synonyms:
5-21-07-00197 (Beilstein Handbook Reference)
5-Methyl-1-phenyl-1H-pyridin-2-one
5-Methyl-1-phenyl-2(1H)-pyridone
5-Methyl-1-phenyl-2-(1H)-pyridone
5-methyl-1-phenylpyridin-2(1H)-one
5-methyl-1-phenylpyridin-2-one
53179-13-8
AC-6797
AC1L2454
AMR 69
AMR-69
BRD-K96862998-001-03-1
BRN 1526549
Bio1_000397
Bio1_000886
Bio1_001375
C093844
C12H11NO
CID40632
D01583
Deskar
EN000704
EU-0100907
Esbriet
F-647
FT-0082541
 
I01-1466
KS-5041
LS-133834
Lopac-P-2116
Lopac0_000907
MLS000860042
NCGC00015806-01
NCGC00015806-03
NCGC00015806-05
NCGC00024992-01
NCGC00024992-02
NCGC00024992-03
P 2116
P2116_SIGMA
PIRFENIDONE
Pirespa
Pirfenidona
Pirfenidona [INN-Spanish]
Pirfenidone (Deskar)
Pirfenidone (JAN/USAN/INN)
Pirfenidone [USAN:INN]
Pirfenidonum
Pirfenidonum [INN-Latin]
S-7701
SMR000326900
Tocris-1093
ZINC00001958
3Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 110956
4Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 113086
5Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 123689
6Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 110729
7VaccinesPhase 46611
8Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113180
9HormonesPhase 4, Phase 3, Phase 2, Phase 114415
10Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113168
11beta-endorphinPhase 4, Phase 2140
12Melanocyte-Stimulating HormonesPhase 4, Phase 2139
13Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 2, Phase 3, Phase 14443
14Adrenocorticotropic HormonePhase 4, Phase 2164
15Analgesics, Non-NarcoticPhase 4, Phase 2, Phase 3, Phase 16501
16AnalgesicsPhase 4, Phase 2, Phase 3, Phase 111733
17
Cyclosporineapproved, investigational, vet_approvedPhase 392279217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
18
Prednisoneapproved, vet_approvedPhase 3, Phase 2139853-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
19
Tacrolimusapproved, investigationalPhase 2, Phase 31102104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
20
BenzocaineapprovedPhase 2, Phase 320161994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
21
Prednisoloneapproved, vet_approvedPhase 3, Phase 2119350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
22
Miconazoleapproved, investigational, vet_approvedPhase 3370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
23
MethotrexateapprovedPhase 3, Phase 215511959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
24
Methylprednisoloneapproved, vet_approvedPhase 3, Phase 2119383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
25
LevoleucovorinapprovedPhase 3, Phase 272868538-85-2
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-formyltetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
 
(S)-Leucovorin
Citrovorum factor
L-Folinic acid
Levofolene
Levofolinic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
26
AlendronateapprovedPhase 2, Phase 3162121268-17-5, 66376-36-12088
Synonyms:
(4-Amino-1-hydroxybutylidene)bisphosphonic acid
(4-Amino-1-hydroxybutylidene)diphosphonic acid
(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
(4-amino-1-hydroxybutylidene)bisphosphonic acid
121268-17-5 (mono-hydrochloride salt, trihydrate)
1yhm
4-Amino-1-hydroxybutane-1,1-diphosphonate
4-Amino-1-hydroxybutane-1,1-diphosphonic Acid
4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid)
4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
4-amino-1-hydroxybutane-1,1-diphosphonic acid
66376-36-1
ABDP
AC1L1CW3
AKOS001015793
ALENDRONATE SODIUM
ALENDRONIC ACID
Acide Alendronique
Acide Alendronique [INN-French]
Acide alendronique
Acide alendronique [INN-French]
Acido Alendronico
Acido Alendronico [INN-Spanish]
Acido alendronico
Acido alendronico [INN-Spanish]
Acidum Alendronicum
Acidum Alendronicum [INN-Latin]
Acidum alendronicum
Acidum alendronicum [INN-Latin]
Adronat
 
Alendronate
Alendronate Sodium
Alendronate sodium hydrate
Alendronic acid
Alendronic acid (INN)
Alendronic acid [INN:BAN]
Alendros
Arendal
BIDD:GT0180
C07752
CHEBI:2567
CHEMBL870
CID2088
D07119
DB00630
Fosamax
Fosamax Plus D
HSCI1_000337
LS-106421
MK 217
MK-217
MolPort-000-421-410
NCGC00096054-01
NCGC00096054-03
NCGC00096054-04
Onclast
Oprea1_422906
Phosphonic acid, (4-amino-1-hydroxybutylidene)bis
SPECTRUM1505166
ST50036159
UNII-X1J18R4W8P
alendronate
bisphosphonate, 65
27
InfliximabapprovedPhase 2, Phase 3392170277-31-3
Synonyms:
 
Ig gamma-1 chain C region
Remicade
28
Cyclophosphamideapproved, investigationalPhase 2, Phase 3, Phase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
29
rituximabapprovedPhase 2, Phase 31692174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
30
Etanerceptapproved, investigationalPhase 2, Phase 3, Phase 1403185243-69-0
Synonyms:
185243-69-0
CD120b
D00742
Enbrel
Enbrel (TN)
Enbrel Sureclick
Etanercept
Etanercept (USAN/INN)
 
Etanercept (genetical recombination)
Etanercept (genetical recombination) (JAN)
TNF-R2
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B precursor
Tumor necrosis factor receptor type II
etanercept
p75
p80 TNF-alpha receptor
31
belimumabapprovedPhase 2, Phase 348356547-88-15957, 10451420
Synonyms:
356547-88-1
Belimumab
Belimumab (USAN)
 
Benlysta
D03068
LymphoStat-B
LymphoStat-B (TN)
belimumab
32
Acetylcysteineapproved, investigationalPhase 2, Phase 3330616-91-112035
Synonyms:
(2R)-2-acetylamino-3-sulfanylpropanoic acid
(R)-2-acetylamino-3-mercaptopropanoic acid
(R)-mercapturic acid
2-Acetylamino-3-mercapto-propionate
2-Acetylamino-3-mercapto-propionic acid
ACC
Acetadote
Acetilcisteina
Acetylcysteine
Acetylcysteinum
Fluimicil Infantil
Fluimucetin
Fluimucil
Flumucetin
Fluprowit
 
L-Acetylcysteine
L-acetylcysteine
L-α-acetamido-β-mercaptopropionic acid
Lysox
Mercapturic acid
Mucolysin
Mucomyst
N-Acety-L-Cysteine
N-Acetyl-3-mercaptoalanine
N-Acetyl-L-(+)-cysteine
N-Acetylcysteine
N-acetyl-L-(+)-cysteine
N-acetyl-L-cysteine
N-acetylcysteine
NAC
Parvolex
Sodium 2-acetamido-3-mercaptopropionate
33tannic acidapproved, NutraceuticalPhase 2, Phase 32016
34
leucovorinapproved, NutraceuticalPhase 3, Phase 2323558-05-954575, 6560146, 143
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formyltetrahydrofolic acid
Acide folinique
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
Folinic acid calcium salt
 
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
L-Leucovorin
L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid
L-leucovorin
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
Levoleucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyl-THF
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Welcovorin
Wellcovorin
folinate
35
Folic Acidapproved, nutraceutical, vet_approvedPhase 3, Phase 2439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
36Prednisolone acetatePhase 3, Phase 21193
37Prednisolone hemisuccinatePhase 3, Phase 21193
38Protective AgentsPhase 3, Phase 27443
39Prednisolone phosphatePhase 3, Phase 21193
40Vitamin B ComplexPhase 3, Phase 24337
41Gastrointestinal AgentsPhase 3, Phase 2, Phase 18402
42Antineoplastic Agents, HormonalPhase 3, Phase 25592
43Autonomic AgentsPhase 3, Phase 210150
44Calcineurin InhibitorsPhase 3, Phase 21622
45Antimetabolites, AntineoplasticPhase 3, Phase 27361
46AntimetabolitesPhase 3, Phase 212054
47AntiemeticsPhase 3, Phase 24022
48Antifungal AgentsPhase 33696
49Anti-Infective AgentsPhase 3, Phase 2, Phase 122062
50Nucleic Acid Synthesis InhibitorsPhase 3, Phase 24962

Interventional clinical trials:

(show top 50)    (show all 76)
idNameStatusNCT IDPhase
1Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune DiseaseUnknown statusNCT00815282Phase 4
2Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic DiseasesUnknown statusNCT01151644Phase 4
3Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of DermatomyositisRecruitingNCT02245841Phase 4
4Abatacept in Juvenile DermatomyositisRecruitingNCT02594735Phase 4
5Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic DermatomyositisNot yet recruitingNCT02821689Phase 4
6Five-year Actively Controlled Clinical Trial in New Onset Juvenile DermatomyositisUnknown statusNCT00323960Phase 3
7Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant TacrolimusUnknown statusNCT00504348Phase 2, Phase 3
8Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)CompletedNCT00335985Phase 3
9Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DMCompletedNCT00651040Phase 3
10Alendronate Osteoporosis StudyCompletedNCT00277251Phase 2, Phase 3
11Anakinra in MyositisCompletedNCT01165008Phase 2, Phase 3
12Treatment With TNF Blockade, Infliximab, in Patients With MyositisCompletedNCT00443222Phase 2, Phase 3
13Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)RecruitingNCT02728752Phase 3
14Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILDRecruitingNCT01862926Phase 2, Phase 3
15Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory MyopathyRecruitingNCT02971683Phase 3
16Belimumab in MyositisRecruitingNCT02347891Phase 2, Phase 3
17Understanding the Pathogenesis and Treatment of Childhood Onset DermatomyositisTerminatedNCT00035958Phase 2, Phase 3
18A Clinical Trial for CTD-ILD TreatmentTerminatedNCT01424033Phase 2, Phase 3
19Abatacept Treatment in Polymyositis and DermatomyositisUnknown statusNCT01315938Phase 2
20Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated CalcinosisCompletedNCT01572844Phase 2
21Acthar in Treatment of Refractory Dermatomyositis and PolymyositisCompletedNCT01906372Phase 2
22Safety and Effectiveness of h5G1.1-mAb for DermatomyositisCompletedNCT00005571Phase 2
23Safety and Efficacy of BAF312 in DermatomyositisCompletedNCT02029274Phase 2
24Methimazole to Treat Polymyositis and DermatomyositisCompletedNCT00001421Phase 2
25Infliximab (Remicade ) to Treat Dermatomyositis and PolymyositisCompletedNCT00033891Phase 2
26Efficacy of an Individual Rehabilitation Program in Polymyositis and DermatomyositisCompletedNCT01415219Phase 2
27Absorption of Corticosteroids in Children With Juvenile DermatomyositisCompletedNCT00004357Phase 2
28Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)CompletedNCT00106184Phase 2
29Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory MyopathiesCompletedNCT00001261Phase 2
30A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or MyositisCompletedNCT00979654Phase 2
31Trial of IMO-8400 in Adult Patients With DermatomyositisRecruitingNCT02612857Phase 2
32Safety, Tolerability, and Efficacy of JBT-101 in Subjects With DermatomyositisRecruitingNCT02466243Phase 2
33Study of IFN-K in DermatomyositisRecruitingNCT02980198Phase 2
34Tocilizumab in the Treatment of Refractory Polymyositis and DermatomyositisRecruitingNCT02043548Phase 2
35A Study In Adults With Moderate To Severe DermatomyositisNot yet recruitingNCT03181893Phase 2
36Denosumab for Glucocorticoid-treated Children With Rheumatic DisordersNot yet recruitingNCT02418273Phase 1, Phase 2
37Efficacy and Tolerability of BAF312 in Patients With Polymyositis and DermatomyositisTerminatedNCT01148810Phase 2
38A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis CutisWithdrawnNCT01918904Phase 2
39Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERDWithdrawnNCT01025739Phase 2
40A Pilot Study of Etanercept in DermatomyositisCompletedNCT00112385Phase 1
41A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or PolymyositisCompletedNCT00533091Phase 1
42Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune DisordersCompletedNCT00010335Phase 1
43Mycophenolate Mofetil in Systemic SclerosisCompletedNCT00433186Phase 1
44Study of Tofacitinib in Refractory DermatomyositisRecruitingNCT03002649Phase 1
45A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune DiseasesRecruitingNCT02780674Phase 1
46Creatine Supplementation in Pediatric RheumatologyUnknown statusNCT01217320
47A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory MyopathyUnknown statusNCT00971828
48Study of the Prevalence of Polymyositis and Dermatomyositis in NormandyCompletedNCT02880527
49Outcome in Patients With Recent Onset Polymyositis and DermatomyositisCompletedNCT01813617
50Hand Function in Patients With Poly- or DermatomyositisCompletedNCT00866125

Search NIH Clinical Center for Dermatomyositis

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: dermatomyositis

Genetic Tests for Dermatomyositis

About this section

Anatomical Context for Dermatomyositis

About this section

MalaCards organs/tissues related to Dermatomyositis:

36
Skin, Lung, Heart, Breast, T cells, Bone, Colon

FMA organs/tissues related to Dermatomyositis:

17
Muscle or

Publications for Dermatomyositis

About this section

Articles related to Dermatomyositis:

(show top 50)    (show all 1278)
idTitleAuthorsYear
1
Juvenile dermatomyositis/polymyositis and lymphoma. (28477693)
2017
2
Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis. (28089977)
2017
3
Race and income affects outcomes in juvenile dermatomyositis. (28434566)
2017
4
Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis. (27803134)
2017
5
Juvenile dermatomyositis positive for anti-DNA mismatch repair enzyme antibodies. (28073708)
2017
6
Environmental factors associated with disease flare in juvenile and adult dermatomyositis. (28444299)
2017
7
Endothelial progenitor cell number is not decreased in 34 children with Juvenile Dermatomyositis: a pilot study. (28514969)
2017
8
Recurrence of juvenile dermatomyositis 8A years after remission. (28050594)
2017
9
Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis. (28463039)
2017
10
Image Gallery: Palmoplantar hyperkeratosis in dermatomyositis with anti-PM/Scl antibodies. (28504398)
2017
11
Paraneoplastic Dermatomyositis. (28457044)
2017
12
Dermatomyositis Patients with Anti-Nuclear Matrix Protein-2 Autoantibodies Have More Edema, More Severe Muscle Disease, and Increased Malignancy Risk. (28085235)
2017
13
Amyopathic Dermatomyositis Associated with Histopathological Findings of Organizing Pneumonia and Pulmonary Vasculitis. (28443580)
2017
14
Juvenile dermatomyositis: a tertiary center experience. (28058540)
2017
15
Positive Association between ANKRD55 Polymorphism 7731626 and Dermatomyositis/Polymyositis with Interstitial Lung Disease in Chinese Han Population. (28470010)
2017
16
Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: Successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column therapy. (27995057)
2017
17
MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis. (28480196)
2017
18
Unsuspected Active Ulcerative Colitis in a Patient With Dermatomyositis: A Rare Association Detected on (18)F-FDG PET/CT During the Search for an Occult Malignancy. (28533643)
2017
19
A case of dermatomyositis with underlying unusual malignancy. (28513483)
2017
20
Anti-dense Fine Speckled 70 Autoantibodies in Japanese Children with Dermatomyositis, Localized Scleroderma, and Idiopathic Arthritis with Iridocyclitis. (28461535)
2017
21
Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. (28077146)
2017
22
Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis. (28460448)
2017
23
Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. (28490218)
2017
24
Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review. (28488124)
2017
25
Successful resection of liver metastasis detected by exacerbation of skin symptom in a patient with dermatomyositis accompanied by rectal cancer: a case report and literature review. (28054279)
2017
26
Anti-NXP2-Positive Paraneoplastic Dermatomyositis With Histopathologic Changes Confined to the Acrosyringia. (28045754)
2017
27
Retinal Manifestations of Juvenile Dermatomyositis: Case Report of Bilateral Diffuse Chorioretinopathy with Paracentral Acute Middle Maculopathy and Review of the Literature. (28448730)
2017
28
Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody. (28451794)
2017
29
Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. (28012490)
2017
30
Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study. (28487565)
2017
31
Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. (27761751)
2016
32
Analysis of sexual function of patients with dermatomyositis and polymyositis through self-administered questionnaires: a cross-sectional study. (27865559)
2016
33
Methotrexate-Associated Classic Hodgkin Lymphoma in a Patient With Dermatomyositis. (27556248)
2016
34
Isaacs' syndrome in a patient with dermatomyositis: case report and review of the literature. (27135791)
2016
35
Dermatomyositis as a symptom of primary lung cancer: A case report and review of the literature. (27123126)
2016
36
Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis. (27588444)
2016
37
Association of vitamin D receptor gene BsmI B/b and FokI F/f polymorphisms with adult dermatomyositis and systemic lupus erythematosus. (26972080)
2016
38
Fatty acid binding protein 3 is associated with skeletal muscle strength in polymyositis and dermatomyositis. (26891180)
2016
39
Transcriptomic profiling of long non-coding RNAs in dermatomyositis by microarray analysis. (27605457)
2016
40
Pulmonary embolism induced by methotrexate in a dermatomyositis patient. (27659404)
2016
41
Two cases of autoimmune and secondary pulmonary alveolar proteinosis during immunosuppressive therapy in dermatomyositis with interstitial lung disease. (26872621)
2016
42
Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options. (27908312)
2016
43
Juvenile dermatomyositis with anti-signal recognition particle antibodies: a case report. (27155307)
2016
44
Treatment of Clinically Amyopathic Dermatomyositis in adults: A Systematic Review. (27167896)
2016
45
Do Muscle Enzyme Changes Forecast Liver Injury in Polymyositis/Dermatomyositis Patients Treated with Methylprednisolone and Methotrexate? (27312550)
2016
46
Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases. (27623619)
2016
47
Case of anti-transcriptional intermediary factor-1-positive dermatomyositis associated with breast cancer developing over 10 years. (27607893)
2016
48
Juvenile dermatomyositis with anti-signal recognition particle antibodies: a case report. (27606477)
2016
49
Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. (27615411)
2016
50
The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists. (28004387)
2016

Variations for Dermatomyositis

About this section

Expression for genes affiliated with Dermatomyositis

About this section
Search GEO for disease gene expression data for Dermatomyositis.

Pathways for genes affiliated with Dermatomyositis

About this section

GO Terms for genes affiliated with Dermatomyositis

About this section

Cellular components related to Dermatomyositis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1aminoacyl-tRNA synthetase multienzyme complexGO:001710110.8IARS, KARS
2NuRD complexGO:001658110.1CHD3, CHD4
3external side of plasma membraneGO:00098979.7ICAM1, IL17A, TNF, VCAM1
4extracellular spaceGO:00056157.7ICAM1, IL17A, IL1A, KARS, S100A9, SFTPD
5cytoplasmGO:00057376.9AARS, CHD3, CHD4, GARS, HARS, IARS

Biological processes related to Dermatomyositis according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1diadenosine tetraphosphate biosynthetic processGO:001596610.7GARS, KARS
2regulation of translational fidelityGO:000645010.7AARS, IARS
3membrane to membrane dockingGO:002261410.6ICAM1, VCAM1
4response to copper ionGO:004668810.5ICAM1, IL1A
5positive regulation of cytokine production involved in inflammatory responseGO:190001710.5IL17A, KARS
6positive regulation of leukocyte adhesion to vascular endothelial cellGO:190499610.4ICAM1, TNF
7leukocyte tethering or rollingGO:005090110.3TNF, VCAM1
8tRNA aminoacylationGO:004303910.3AARS, TARS
9translationGO:00064129.3AARS, GARS, HARS, IARS, KARS, TARS
10tRNA aminoacylation for protein translationGO:00064189.3AARS, GARS, HARS, IARS, KARS, TARS
11viral processGO:00160328.6ICAM1, IFIH1, KARS, MORC3, VCAM1

Molecular functions related to Dermatomyositis according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydridesGO:001681810.7CHD3, CHD4
2aminoacyl-tRNA editing activityGO:000216110.7AARS, IARS
3integrin bindingGO:000517810.2ICAM1, UTRN, VCAM1
4ligase activity, forming aminoacyl-tRNA and related compoundsGO:001687610.1AARS, TARS
5tRNA bindingGO:00000499.7AARS, IARS, KARS
6aminoacyl-tRNA ligase activityGO:00048129.4AARS, GARS, HARS, IARS, KARS, TARS
7ligase activityGO:00168749.1AARS, GARS, HARS, IARS, KARS, TARS
8ATP bindingGO:00055248.1AARS, CHD3, CHD4, CHKB, GARS, HARS

Sources for Dermatomyositis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet